60 Degrees Pharmaceuticals, Inc. (SXTP), a pharmaceutical company focused on developing treatments for infectious diseases, announced that it has received Investigational Review Board or IRB approval for its Phase II clinical study to evaluate tafenoquine or ARAKODA as a potential treatment for chronic babesiosis.
The open-label study will assess the efficacy and safety of tafenoquine over a 90-day treatment period for patients with a presumptive diagnosis of chronic babesiosis.
For comments and feedback contact: editorial@rttnews.com
September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.